Nationwide oncological networks for resection of colorectal liver metastases in the Netherlands: Differences and postoperative outcomes.
Aged
Aged, 80 and over
Carcinoma
/ secondary
Colorectal Neoplasms
/ pathology
Diagnosis-Related Groups
Female
Hepatectomy
Hospital Planning
Hospitals
Humans
Liver Neoplasms
/ secondary
Magnetic Resonance Imaging
Male
Metastasectomy
Middle Aged
Mortality
Neoadjuvant Therapy
Netherlands
Postoperative Complications
/ epidemiology
Tertiary Care Centers
Colorectal liver metastases
Oncological networks
Outcomes
Variation
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
09
04
2021
revised:
29
08
2021
accepted:
02
09
2021
pubmed:
22
11
2021
medline:
8
3
2022
entrez:
21
11
2021
Statut:
ppublish
Résumé
Widespread differences in patient demographics and disease burden between hospitals for resection of colorectal liver metastases (CRLM) have been described. In the Netherlands, networks consisting of at least one tertiary referral centre and several regional hospitals have been established to optimize treatment and outcomes. The aim of this study was to assess variation in case-mix, and outcomes between these networks. This was a population-based study including all patients who underwent CRLM resection in the Netherlands between 2014 and 2019. Variation in case-mix and outcomes between seven networks covering the whole country was evaluated. Differences in case-mix, expected 30-day major morbidity (Clavien-Dindo ≥3a) and 30-day mortality between networks were assessed. In total 5383 patients were included. Thirty-day major morbidity was 5.7% and 30-day mortality was 1.5%. Significant differences between networks were observed for Charlson Comorbidity Index, ASA 3+, previous liver resection, liver disease, preoperative MRI, preoperative chemotherapy, ≥3 CRLM, diameter of largest CRLM ≥55 mm, major resection, combined resection and ablation, rectal primary tumour, bilobar and extrahepatic disease. Uncorrected 30-day major morbidity ranged between 3.3% and 13.1% for hospitals, 30-day mortality ranged between 0.0% and 4.5%. Uncorrected 30-day major morbidity ranged between 4.4% and 6.0% for networks, 30-day mortality ranged between 0.0% and 2.5%. No negative outliers were observed after case-mix correction. Variation in case-mix and outcomes are considerably smaller on a network level as compared to a hospital level. Therefore, auditing is more meaningful at a network level and collaboration of hospitals within networks should be pursued.
Identifiants
pubmed: 34801321
pii: S0748-7983(21)00727-7
doi: 10.1016/j.ejso.2021.09.004
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-448Investigateurs
Cornelis H C Dejong
(CHC)
Marc G H Besselink
(MGH)
Marieke T de Boer
(MT)
Andries E Braat
(AE)
Jeroen Hagendoorn
(J)
Frederik J H Hoogwater
(FJH)
I Quintus Molenaar
(IQ)
Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.